OncoMatch/Clinical Trials/NCT04944914
Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma
Is NCT04944914 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies camrelizumab for nasopharyngeal carcinoma.
Treatment: camrelizumab — We intend to compare the efficacy and safety of immunotherapy plus stereotactic body radiotherapy at oligometastatic lesions and immunotherapy alone among patients with oligometastatic nasopharyngeal carcinoma whose primary lesion has been well controlled after radical local-regional treatment through this multicenter randomized phase 3 trial.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic chemotherapy — first-line
Underwent at least first-line systemic chemotherapy, regardless of regimen and curative effect.
Must have received: radical radiotherapy — primary lesion and regional lymph nodes
Primary lesion and regional lymph nodes completed radical radiotherapy 3 months before stereotactic body radiotherapy and diseases well controlled.
Cannot have received: immunotherapy (PD-1/PD-L1 or CTLA-4 monoclonal antibody)
Immunotherapy (PD-1/PD-L1 or CTLA-4 monoclonal antibody) failure.
Cannot have received: chemotherapy (cytotoxic or molecular targeted)
chemotherapy (cytotoxic or molecular targeted) within 4 weeks before stereotactic body radiotherapy.
Lab requirements
Cardiac function
chd no less than grade 2, arrhythmia (qtc interval over 450ms for male and 470ms for female) or cardiac insufficiency [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify